• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Sinovac Biotech, Ltd.

    4/30/25 6:01:50 AM ET
    $SVA
    Major Pharmaceuticals
    Health Care
    Get the next $SVA alert in real time by email
    6-K 1 tm2513485d1_6k.htm FORM 6-K

     

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

    THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of April 2025

     

     

     

    Commission File Number: 001-32371

     

     

     

    SINOVAC BIOTECH LTD.

     

    No. 39 Shangdi Xi Rd, Haidian District

    Beijing 100085, People’s Republic of China

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

    Form 20-F     x            Form 40-F     ¨

     

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

     

      SINOVAC BIOTECH LTD.
           
           
      By:  

    /s/ Chiang Li

      Name: Dr. Chiang Li
      Title: Chairman of the Board of Directors

     

    Date: April 30, 2025

     

     

     

    Exhibit Index

     

    Exhibit 99.1Press Release – SINOVAC Announces Record and Distribution Dates for Special Cash Dividend

     

    Exhibit 99.2Press Release – SINOVAC Board Issues Letter to Shareholders to Set the Record Straight on the Hostile Actions and False Claims by Vivo Capital

     

     

    Get the next $SVA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SVA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SVA
    SEC Filings

    See more
    • SEC Form 6-K filed by Sinovac Biotech, Ltd.

      6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)

      6/18/25 9:04:51 PM ET
      $SVA
      Major Pharmaceuticals
      Health Care
    • SEC Form 6-K filed by Sinovac Biotech, Ltd.

      6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)

      6/18/25 2:09:19 PM ET
      $SVA
      Major Pharmaceuticals
      Health Care
    • SEC Form 6-K filed by Sinovac Biotech, Ltd.

      6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)

      6/18/25 8:03:53 AM ET
      $SVA
      Major Pharmaceuticals
      Health Care

    $SVA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SINOVAC Board of Directors Prevails Against Advantech/Prime's New York Lawsuit

      New York Court Denies Advantech/Prime's Petition for Emergency Injunctive Relief Clears Legal Hurdle for Dividend Paying Agent to Payout the Special Cash Dividend of US$55.00 Per Common Share on July 7, 2025 SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced it has prevailed against Advantech/Prime Success' ("Advantech/Prime") Petition for Emergency Injunctive Relief in the U.S. District Court for the Southern District of New York. The result in the New York court represents another failure in the campaign by Advantech/Prime in coordination with Vivo Capital (together known as the "Dissenting Inves

      6/20/25 10:56:00 PM ET
      $SVA
      Major Pharmaceuticals
      Health Care
    • SINOVAC Board of Directors Files Definitive Proxy Materials

      Files definitive proxy statement and mails letter to shareholders Urges shareholders to VOTE the WHITE proxy card and vote "AGAINST" the misguided proposals to remove SINOVAC's Board and appoint the Reconstituted Imposter Former Board Slate The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced it has filed its definitive proxy materials with the Securities and Exchange Commission (SEC) for the Special Meeting of Shareholders to be held on Wednesday, July 9, 2025 at 8:00 a.m. China Standard Time (Tuesday, July 8, 2025 at 8:00 p.m. Atlantic Standard Time). In conjunction with t

      6/18/25 2:18:00 PM ET
      $SVA
      Major Pharmaceuticals
      Health Care
    • SINOVAC Announces New Board Member

      Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received a resignation notice from David Guowei Wang, a member of the board of directors (the "Board") and a member of the Audit Committee, Compensation Committee and the Corporate Governance and Nominating Committee of the Board, effective immediately. Mr. Wang's resignation was due to increased professional commitments and time constraints and was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. The Board has appointed Geoffrey C. Hsu, CFA, as a director to the Boar

      6/18/25 4:38:00 AM ET
      $SVA
      Major Pharmaceuticals
      Health Care

    $SVA
    Financials

    Live finance-specific insights

    See more
    • SINOVAC Board of Directors Prevails Against Advantech/Prime's New York Lawsuit

      New York Court Denies Advantech/Prime's Petition for Emergency Injunctive Relief Clears Legal Hurdle for Dividend Paying Agent to Payout the Special Cash Dividend of US$55.00 Per Common Share on July 7, 2025 SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced it has prevailed against Advantech/Prime Success' ("Advantech/Prime") Petition for Emergency Injunctive Relief in the U.S. District Court for the Southern District of New York. The result in the New York court represents another failure in the campaign by Advantech/Prime in coordination with Vivo Capital (together known as the "Dissenting Inves

      6/20/25 10:56:00 PM ET
      $SVA
      Major Pharmaceuticals
      Health Care
    • SINOVAC Board of Directors Files Definitive Proxy Materials

      Files definitive proxy statement and mails letter to shareholders Urges shareholders to VOTE the WHITE proxy card and vote "AGAINST" the misguided proposals to remove SINOVAC's Board and appoint the Reconstituted Imposter Former Board Slate The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced it has filed its definitive proxy materials with the Securities and Exchange Commission (SEC) for the Special Meeting of Shareholders to be held on Wednesday, July 9, 2025 at 8:00 a.m. China Standard Time (Tuesday, July 8, 2025 at 8:00 p.m. Atlantic Standard Time). In conjunction with t

      6/18/25 2:18:00 PM ET
      $SVA
      Major Pharmaceuticals
      Health Care
    • SINOVAC Board of Directors Provides Update on Special Dividend Payment and Commitment to Delivering Value to All Shareholders

      Accelerates payment of previously announced special cash dividend of US$55.00 per common share Decides to declare second special cash dividend of US$19.00 per common share Intends to declare third special cash dividend between US$20.00 – US$50.00 per common share Adopts new dividend policy to regularly return cash to shareholders The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced several important decisions to deliver sustainable value to shareholders and strengthen the Company's governance framework. Currently, a dissenting investor group led by Advantech/Prime Succes

      6/17/25 1:52:00 PM ET
      $SVA
      Major Pharmaceuticals
      Health Care

    $SVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Sinovac Biotech, Ltd.

      SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

      9/12/24 4:03:46 PM ET
      $SVA
      Major Pharmaceuticals
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Sinovac Biotech, Ltd.

      SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

      6/17/24 4:02:44 PM ET
      $SVA
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by Sinovac Biotech, Ltd. (Amendment)

      SC 13G/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

      3/20/24 7:33:23 AM ET
      $SVA
      Major Pharmaceuticals
      Health Care

    $SVA
    Leadership Updates

    Live Leadership Updates

    See more
    • SAIF Partners Files Definitive Proxy Materials in Connection with Sinovac Biotech 2025 Special Meeting of Shareholders; Nominates Ten Highly Qualified Director Candidates to the Board

      Sends Open Letter to Sinovac Shareholders Calling for a New Board to End Years of Chaos at Sinovac SAIF Nominees Will Work to Resolve Costly Legal Battles, Take Action to Resume Stock Trading after Six-Year Halt, and Facilitate Distribution of Cash That Rightfully Belongs to Shareholders Urges Sinovac Shareholders to VOTE the GOLD Proxy Card FOR the Election of SAIF's Director Nominees SAIF Partners IV L.P., ("SAIF Partners"), the largest single investor in Sinovac Biotech Ltd. ("Sinovac" or the "Company"), beneficially owning approximately 15% of the outstanding common shares, today announced that it has filed a definitive proxy statement for the election of ten director nominees to

      6/16/25 11:52:00 AM ET
      $SVA
      Major Pharmaceuticals
      Health Care
    • Vivo Capital Issues Letter to Sinovac Biotech Shareholders Addressing the Company's False and Misleading Claims

      Affirms Support for Fair and Equitable Dividend Distribution for All Shareholders by Sinovac Corrects the Company's Misrepresentations of Vivo's Capital Contributions, Which Have Been Critical to Sinovac's Commercial Success and Ability to Return Capital to Shareholders Calls on All Shareholders to Stand up for Transparent Corporate Governance and Elect Qualified Directors to the Board at Upcoming Special Meeting on July 8 Vivo Capital ("Vivo" or "we"), a leading global investment firm focused exclusively on healthcare and life sciences and an approximately 8% shareholder in Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company"), today sent a letter to shareholders. *** D

      6/11/25 8:30:00 AM ET
      $SVA
      Major Pharmaceuticals
      Health Care
    • Heng Ren Partners Demands Sinovac Distribute $8.9 Billion in Cash to its Shareholders and Cause Reinstatement of Trading

      BOSTON, March 20, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac") shareholder Heng Ren Partners, LLC funds ("Heng Ren") today sent an open letter to Sinovac's shareholders outlining the significant and decisive action that Sinovac's Board of Directors must take to create liquidity and release cash to shareholders. Specifically, Heng Ren demands that Sinovac's Board of Directors announce a distribution of $8.9 billion in cash to its shareholders and cause the resumption of trading of the Company's shares. The full text of the letter follows: March 20, 2025 Dear Fellow Sinovac Shareholders: Like you, we are shareholders in Sinovac Biotech Ltd. ("Sinovac" or the "Company").

      3/20/25 11:05:00 AM ET
      $SVA
      Major Pharmaceuticals
      Health Care